卵巢癌诊断前使用绝经激素治疗与生存改善相关
该研究纳入卵巢癌协会联盟15项研究的6419例病理确诊的绝经后卵巢癌女性,分析诊断前绝经激素治疗(MHT)与生存的关系。诊断前使用雌激素单药(ET)或雌孕激素联合(EPT)至少5年与更好的卵巢癌生存相关(HR 0.80,95%CI 0.74–0.87)。在晚期高级别浆液性癌中,MHT使用与初次减瘤术后肉眼残留病灶减少相关(使用时长趋势P<0.01),残留病灶介导了17%的MHT与生存关系。
要点
- 诊断前使用ET或EPT至少5年与更好的卵巢癌生存相关(HR 0.80,95%CI 0.74–0.87)。
- 晚期高级别浆液性癌中,MHT使用与初次减瘤术后无肉眼残留病灶相关(使用时长趋势P<0.01)。
- 残留病灶介导了17%的MHT与生存之间的关系。
核心结论
- 诊断前使用MHT至少5年是卵巢癌女性的有利预后因素。
- 这项大型研究与此前较小研究一致,需要进一步工作以理解潜在机制。
研究设计与样本
- 卵巢癌协会联盟15项研究数据的汇总分析,纳入6419例病理确诊的绝经后卵巢癌女性。
- 采用Cox比例风险模型估计激素治疗使用与生存的关联,采用逻辑回归和中介分析探讨MHT使用与减瘤术后残留病灶的关系。
主要发现
- 诊断前使用ET或EPT至少5年与更好的卵巢癌生存相关(HR 0.80,95%CI 0.74–0.87)。
- 在晚期高级别浆液性癌女性中,使用MHT者初次减瘤术后出现任何肉眼残留病灶的可能性更低(MHT使用时长趋势P<0.01)。
- 残留病灶介导了17%的MHT与生存之间的关系。
局限性
- 需要进一步工作以理解潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival. METHODS: Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery. RESULTS: Use of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend <0.01 for duration of MHT use). Residual disease mediated some (17%) of the relationship between MHT and survival. CONCLUSIONS: Pre-diagnosis MHT use for 5+ years was a favorable prognostic factor for women with ovarian cancer. This large study is consistent with prior smaller studies, and further work is needed to understand the underlying mechanism.
引用
- Brieger KK, Peterson S, Lee AW, et al. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecol Oncol. 2020. PMID: 32641237. doi:10.1016/j.ygyno.2020.06.481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。